设为首页 加入收藏

TOP

Noxafil 40 mg/ml oral suspensionPatient’s LeafletSummary for
2013-11-29 22:49:26 来源: 作者: 【 】 浏览:423次 评论:0

For doctors

 

What is it and how is it used?

Noxafil works by killing or stopping the growth of some types of fungi that can cause infections in humans. It belongs to a group of medicines called triazole antifungal agents. These medicines are used to prevent and treat many different infections caused by fungi.

Noxafil can be used to treat the following types of fungal infections in adults:

Noxafil can be used to prevent fungal infections in patients whose immune systems may be weakened due to chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) or in patients using high-dose immunosuppressive therapy following hematopoietic stem cell transplant (HSCT).

What do you have to consider before using it?

Do not take Noxafil

Please see the section “Taking other medicines” for information on other medicines which may interact with Noxafil.

Take special care with Noxafil
Ask your doctor or pharmacist for advice before taking any medicine. Tell your doctor:

Use in children
Please note that Noxafil is only for use in adults (older than 18 years of age).

Taking other medicines
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Please look at the list of medicines given above that must not be taken while you are taking Noxafil. In addition to the medicines named above that must not be taken with posaconazole because of the risk of heart rhythm disturbances, there are other medicines that carry a risk of rhythm problems that may be greater when they are taken with posaconazole. Please make sure you tell your doctor about all the medicines you are taking (prescribed or non prescribed).
There are other medicines that can sometimes be given while you are taking Noxafil but special care may be needed.

Certain medicines may increase the risk of side effects of Noxafil by increasing the amount of Noxafil in the blood. Similarly, certain medicines may decrease the effectiveness of Noxafil by decreasing the amount of posaconazole in the blood.
Medicines that can decrease the effectiveness of Noxafil are:

Noxafil may possibly increase the risk of side effects of some other medicines by increasing the amount of these medicines in the blood. These are:

Taking Noxafil with food and drink
To improve absorption of posaconazole, whenever possible it should be taken during or immediately after food or a nutritional drink (see section 3 “How to take Noxafil”). There is no information on the effect of alcohol on posaconazole.

Pregnancy and breast-feeding
Tell your doctor if you are or think you are pregnant before you start to take Noxafil. Do not use Noxafil during pregnancy unless you are told by your doctor. You should use effective contraception while you are taking Noxafil if you are a woman who could become pregnant. Contact your doctor immediately if you become pregnant while being treated with Noxafil.

Do not breast-feed while being treated with Noxafil, as it cannot be excluded that posaconazole may pass into breast milk.

Driving and using machines
Since posaconazole has been associated with some side effects (dizziness, sleepiness, blurred vision), which may interfere with such ability, please inform your doctor if you experience any effects that may cause you to have problems with driving or using other machinery.

Important information about some of the ingredients of Noxafil
Noxafil contains approximately 1.75 g of glucose per 5 ml of suspension. You should not take this medicine if you have a condition called glucose-galactose malabsorption and should take note of this amount of glucose if you need to watch your sugar intake for any reason.

How is it used?

Always take Noxafil exactly as your doctor has told you. Your doctor will monitor your response and condition to determine how long Noxafil needs to be given and whether any change is needed to your daily dose.

The table below shows the usual dose and length of treatment which depend on the type of infection that you have and may be individually adapted for you by your doctor. Do not adapt your dose yourself before consulting your doctor or change your treatment regime.

Whenever possible you should take posaconazole during or after a meal or a nutritional drink.

Indication Usual dose and length of treatment Treatment of refractory Fungal Infections Invasive aspergillosis, Fusariosis, ChromoblastomycosisMycetoma, Coccidioidomycosis The usual dose is 200 mg one 5 ml spoonful taken four times daily. Alternatively, if recommended by your doctor, you may take 400 mg two 5 ml spoonfuls twice a day provided that you are able to take both doses during or after food or a nutritional drink. First time treatment of Thrush On the first day of treatment take 200 mg one 5 ml spoonful once. After the first day, take 100 mg 2.5 ml once a day. Take 200 mg one 5 ml spoonful three times a day. Prevention of serious Fungal Infections

If you take more Noxafil than you should
If you are concerned that you may have taken too much, contact your doctor or healthcare professional immediately.

If you forget to take Noxafil
If you have missed a dose, take it as soon as you remember and then carry on as before. However, if it is almost time for your next dose, take your dose when it is due. Do not take a double dose to make up for a forgotten dose.

What are possible side effects?

Like all medicines, Noxafil can cause side effects, although not everybody gets them.

Some of these side effects can be serious and may require urgent medical attention. Please consult your doctor immediately if you notice any of the following:

Possible side effects listed below are grouped by frequency of occurrence Very common Common Uncommon Rare Very rare Not known affects more than 1 user in 10 affects 1 to 10 users in 100 affects 1 to 10 users in 1,000 affects 1 to 10 users in 10,000 affects less than 1 user in 10,000 frequency cannot be estimated from the available data

Common side effects:
Abnormal levels of salts in the blood (e.g. could experience confusion and weakness).

Uncommon side effects:
Anaemia, thrombocytopenia (a blood disease characterized by an abnormally small number of platelets in the blood, which may lead to bleeding), leukopenia (a blood disease characterized by lower than the normal amount of white blood cells), eosinophilia (an abnormal increase in the number of a specific type of white blood cell called eosinophils, which often accompanies inflammatory conditions), Allergic reaction,
Convulsions, a problem with the functioning of all the nerves in the body,
Irregular heartbeat, abnormal electrocardiogram, high or low blood pressure,
Inflammation of the pancreas (e.g. intense stomach pain),
Failure of the liver (e.g.coma), liver damage, yellow colour of the skin or the eyes, inflammation of the liver with or without bile obstruction,
Enlargement of both the liver and spleen (e.g. feeling mass under the ribs), liver tenderness, Failure of the kidneys (e.g. urine increase or decrease, discoloured urine, pain while urinating).

Rare side effects:
Pneumonia (e.g. shortness of breath and discoloured phlegm), high blood pressure in the pulmonary artery which can irrevocably damage the lungs and heart,
Unusual blood clotting, prolonged bleeding,
Severe allergic reactions, including widespread blistering rash and skin peeling,
Altered brain function (such as hearing voices or seeing things that are not there), fainting,

Problem thinking or talking, an abnormal tremor consisting of involuntary jerking movements,

especially in the hands, frequently occurring with impending hepatic coma and altered brain function,

Stroke (e.g. pain, weakness, numbness, or tingling in the limbs),
A blind or dark spot in the visual field,
Heart failure or heart attack, heart rhythm disorders, with sudden death, absence of the heart beat leading to oxygen lack and eventually to death,
Blood clots in limbs (e.g. intense pain or swelling), or blood clots in lungs (e.g. shortness of breath, pain while breathing),
Bleeding into the gut (e.g. vomiting blood, blood in the stool), intestinal obstruction: blockage of the intestine (especially the ileum) that prevents the contents of the intestine from passing to the lower bowel, which often results in abdominal bloating, vomiting, severe constipation, loss of appetite, and cramps,
Haemolytic uraemic syndrome (a condition characterized by the breakup of red blood cells (hemolysis) with or without kidney failure), pancytopenia (an abnormal deficiency in all blood cells (red blood cells, white blood cells and platelets)),
Large purple discolourations on the skin,
Swelling of the face or tongue.

The other side effects listed below are given with an estimation of the frequency with which they may occur with Noxafil.

Common side effects:
An abnormal sensation of the skin, such as numbness, tingling, pricking, burning, or creeping on the skin,
Headache, dizziness,
Sleepiness,
Nausea (feeling or being sick), loss of appetite, stomach pain, diarrhoea, upset stomach, vomiting, passing gas, dry mouth,
Abnormal liver function results in blood test,
A decrease in white blood cells in blood tests (that can increase the risk of infections), Weakness, tiredness,
Rash,
Fever.

Uncommon side effects:
Enlargement of lymph glands,
Reduced sense of touch or sensation, or a partial loss of sensitivity to sensory stimuli,, tremor, High blood levels of sugar,
Blurred vision,
Temporary hair loss,
Mouth ulcers,
Shivering, generally feeling unwell,
Scattered body pain, including in muscles and joints, back pain,
Water retention (e.g. body swelling),
Menstrual disorder (e.g. abnormal bleeding from the vagina),
Change in effectiveness of some medicines.

Rare side effects:

Depression,
Double vision,

Breast pain,
Poor functioning of the adrenal gland (e.g. weakness, fatigue, loss of appetite, skin discolouration), decreased blood levels of hormones that are secreted by the pituitary gland, and that affect the function of the male or female gonads,
Hearing problems.

Some patients have also reported feeling confused after taking Noxafil.

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

How should it be stored?

Keep out of the reach and sight of children.

Do not use Noxafil after the expiry date which is stated on the label. The expiry date refers to the last day of that month.

Do not freeze.

If you have any suspension left in a bottle more than four weeks after it was first opened, you should not use this medicine. Please return the bottle containing any left over suspension to your pharmacist.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

↑ back to table of contents ↑

For doctors

What is it?

Noxafil is an oral suspension that contains the active substance posaconazole (40 mg/ml).

What is it used for?

Noxafil is an antifungal medicine. It is used to treat adults (aged 18 years or over) with the following fungal diseases, when treatments with other antifungal medicines (amphotericin B, itraconazole or fluconazole) cannot be tolerated or have failed:

Noxafil is also used as a first-line treatment for ‘thrush’, a fungal infection of the mouth and throat due to Candida. It is used in patients whose infection is severe or patients with weakened immune systems, when medicines applied topically (directly on the thrush) are unlikely to work.

Noxafil is also used to prevent invasive fungal infections in patients whose immune system is weakened because of treatments they are receiving for blood or bone marrow cancers or medicines used in haematopoietic stem cell transplantation (a transplant of cells that make blood cells).

The medicine can only be obtained with a prescription.

How is it used?

Noxafil treatment should be started by a doctor who has experience in managing fungal infections or in treating patients at high risk of invasive fungal infections.

Noxafil is taken by mouth with a meal or nutritional supplement. The suspension must be shaken well before use.

For the treatment of fungal infections, with the exception of candidiasis, Noxafil is taken at a dose of 400 mg (10 ml) twice a day, or 200 mg (5 ml) four times a day in patients who cannot tolerate a meal. The duration of treatment depends on the severity of the disease and the patient’s response. For candidiasis, Noxafil is taken as 200 mg (5 ml) on the first day followed by 100 mg (2.5 ml) once a day for the following 13 days.

For the prevention of invasive fungal infections, Noxafil is given at a dose of 200 mg (5 ml) three times a day. The duration of treatment depends on the patient’s condition.

How does it work?

The active substance in Noxafil, posaconazole, is an antifungal medicine that belongs to the triazoles group. It works by preventing the formation of ergosterol, which is an important part of fungal cell walls. Without ergosterol, the fungus dies or is prevented from spreading. The list of fungi against which Noxafil is active can be found in the summary of product characteristics (also part of the EPAR).

How has it been studied?

In one main study, Noxafil was studied in 238 patients with invasive fungal infections that did not respond to standard antifungal treatment. The study included 107 patients with aspergillosis, 18 patients with fusariosis, 11 with chromoblastomycosis or mycotema, and 16 with coccidioidomycosis. The results obtained with Noxafil were compared with the records of 218 patients who were treated with other antifungal medicines. In another main study involving 350 HIV-infected patients with oropharyngeal candidiasis, Noxafil was compared with fluconazole. In both studies, the main measure of effectiveness was the number of patients with a complete or partial response to treatment.

The ability to prevent infections was investigated in two additional main studies, where Noxafil was compared with fluconazole in 600 stem cell transplant patients and with fluconazole or itraconazole in 602 patients with blood or bone marrow cancer. The studies looked at the number of patients who developed an invasive fungal infection .

What benefits has it shown during the studies?

In invasive aspergillosis, a successful response at the end of treatment was seen in 42% of the patients taking Noxafil, compared with 26% of the patients in the comparator group. Noxafil also successfully treated 11 of the 18 patients who had proven or probable fusariosis, 9 of the 11 patients with chromoblastomycosis or mycetoma, and 11 of the 16 patients with coccidioidomycosis.

In oropharyngeal candidiasis, Noxafil was as effective as fluconazole. After 14 days of treatment, both medicines had been successful in curing or improving about 92% of patients.

In the prevention studies, Noxafil was as effective as fluconazole in stem cell transplant patients, with 5% of patients developing an infection in the Noxafil group, and 9% in the comparator group. The medicine was more effective than fluconazole or itraconazole in cancer patients, with 2% of patients developing an infection in the Noxafil group, and 8% in the comparator groups.

What is the risk associated?

The most common side effects with Noxafil (seen in between 1 and 10 patients in 100) are neutropenia (low white blood cell count), electrolyte imbalance, lack of appetite, dizziness, paresthesia (pins and needles), somnolence (sleepiness), headache, vomiting, nausea (feeling sick), abdominal pain (stomach ache), diarrhoea, dyspepsia (indigestion), dry mouth, flatulence (gas), signs of liver damage in the blood, rash, asthenia (weakness), fatigue (tiredness) and pyrexia (fever). For the full list of all side effects reported with Noxafil, see the package leaflet.

Noxafil should not be used in people who may be hypersensitive (allergic) to posaconazole or any of the other ingredients. Noxafil must not be used in patients who are taking any of the following medicines:

Caution is also needed when Noxafil is taken at the same time as other medicines. See the Package Leaflet for full details.

Why has it been approved?

The CHMP concluded that, although the first study compared Noxafil with records of patients who were actually enrolled in that study, the effectiveness of Noxafil was shown. The Committee decided that Noxafil’s benefits are greater than its risks and recommended that it be given marketing authorisation.

Further information

The European Commission granted a marketing authorisation valid throughout the European Union, for Noxafil to Schering-Plough Europe on 25 October 2005. The marketing authorisation is valid for an unlimited period.

For more information about treatment with Noxafil, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

This summary was last updated in 08-2010.

↑ back to table of contents ↑
 

Name

 

Noxafil 40 mg/ml oral suspension

 

Composition

 

Each ml of oral suspension contains 40 mg of posaconazole.

Excipients:
This medicinal product contains approximately 1.75 g of glucose per 5 ml of suspension.

For a full list of excipients, see section 6.1.

 

Pharmaceutical Form

 

Oral suspension

White suspension

Are you an Healthcare Professional? Access professional drug leaflets on Diagnosia.com!

以下是“全球医药”详细资料
Tags: 责任编辑:admin
】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
分享到QQ空间
分享到: 
上一篇Noxafil 40 mg/ml suspension buv.. 下一篇ARICEPT

相关栏目

最新文章

图片主题

热门文章

推荐文章

相关文章

广告位